Timing of In-Hospital Coronary Artery Bypass Graft Surgery for Non–ST-Segment Elevation Myocardial Infarction Patients Results From the National Cardiovascular Data Registry ACTION Registry–GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With The Guidelines) by Parikh, Shailja V. et al.
T
G
M
R
A
O
S
E
T
E
A
D
O
s
B
t
d
M
h
P
A
(
(
o
N
R
m
d
h
a
s
b
C
h
w
s
a
I
F
o
C
r
M
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 3 , N O . 4 , 2 0 1 0
© 2 0 1 0 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / 1 0 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 0 . 0 1 . 0 1 2iming of In-Hospital Coronary Artery Bypass
raft Surgery for Non–ST-Segment Elevation
yocardial Infarction Patients
esults From the National Cardiovascular Data Registry
CTION Registry–GWTG (Acute Coronary Treatment and Intervention
utcomes Network Registry–Get With The Guidelines)
hailja V. Parikh, MD,* James A. de Lemos, MD,* Michael E. Jessen, MD,†
mmanouil S. Brilakis, MD, PHD,* E. Magnus Ohman, MD,‡ Anita Y. Chen, MS,‡
racy Y. Wang, MD, MHS,‡ Eric D. Peterson, MD, MPH,‡ Matthew T. Roe, MD, MHS,‡
lizabeth M. Holper, MD, MPH,* on behalf of the CRUSADE and
CTION Registry–GWTG Participants
allas, Texas; and Durham, North Carolina
bjectives The aim of this study was to examine timing of in-hospital coronary artery bypass graft
urgery (CABG) for non–ST-segment elevation myocardial infarction (NSTEMI) patients.
ackground Although practice guidelines recommend delaying CABG for a few days after presenta-
ion for ST-segment elevation myocardial infarction patients, current guidelines for NSTEMI patients
o not address optimal CABG timing.
ethods We evaluated rates and timing of in-hospital CABG among NSTEMI patients treated at U.S.
ospitals from 2002 to 2008 with the CRUSADE (Can Rapid Risk Stratiﬁcation of Unstable Angina
atients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/
merican Heart Association Guidelines) (January 2002 to December 2006) and ACTION Registry–GWTG
Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With The Guidelines)
January 2007 to June 2008) programs. Analyses designed to study the clinical characteristics and
utcomes of early (48 h, n  825) versus late (48 h, n  1,822) CABG focused upon more recent
STEMI patients from the ACTION Registry–GWTG.
esults Both the rate (11% to 13%) and timing (30% early and 70% late) of in-hospital CABG re-
ained consistent from 2002 to 2008. In the ACTION Registry–GWTG program, NSTEMI patients un-
ergoing late CABG tended to have a higher risk proﬁle than those undergoing early CABG. In-
ospital mortality (3.6% vs. 3.8%, adjusted odds ratio: 1.12, 95% conﬁdence interval: 0.71 to 1.78)
nd the composite outcome of death, myocardial infarction, congestive heart failure, or cardiogenic
hock (12.6% vs. 12.4%, adjusted odds ratio: 0.94, 95% conﬁdence interval: 0.69 to 1.28) were similar
etween patients undergoing early versus late CABG.
onclusions Most NSTEMI patients undergo late CABG after hospital arrival. Although these patients
ave higher-risk clinical characteristics, they have the same risk of adverse clinical outcomes compared
ith patients who undergo early CABG. Thus, delaying CABG routinely after NSTEMI might increase re-
ource use without improving outcomes. Additionally, the timing of CABG for NSTEMI patients might be
ppropriately determined by clinicians to minimize the risk of adverse clinical events. (J Am Coll Cardiol
ntv 2010;3:419–27) © 2010 by the American College of Cardiology Foundation
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420ore than 40% of patients with an acute coronary syndrome
ave multivessel coronary artery disease identified at the time
f coronary angiography (1). Thus, coronary artery bypass graft
urgery (CABG) might be recommended for revascularization.
ecause a number of previous studies have reported increased
ortality associated with early CABG after ST-segment ele-
ation myocardial infarction (STEMI) (2–12), the American
ollege of Cardiology/American Heart Association STEMI
uidelines recommend delaying CABG in stable patients to
inimize risk (13). However, the optimal timing of CABG
fter non–ST-segment elevation myocardial infarction
NSTEMI) is not addressed in the most recent American
ollege of Cardiology/American Heart Association Guide-
ines for Unstable Angina and NSTEMI (14).
See page 428
We used the CRUSADE (Can
Rapid Risk Stratification of Un-
stable Angina Patients Suppress
Adverse Outcomes with Early
Implementation of the American
College of Cardiology/American
Heart Association Guidelines)
and ACTION Registry–GWTG
(Acute Coronary Treatment and
Intervention Outcomes Network
Registry–Get With The Guide-
lines) databases to determine
whether the use and timing of
in-hospital CABG for NSTEMI
patients has changed over the past
6 years and to examine the influ-
ence of the timing of CABG on
in-hospital outcomes.
Methods
ata sources. The NCDR (National Cardiovascular Data,
egistry) ACTION Registry–GWTG represents a merger of
he prior National Registry for Myocardial Infarction and
RUSADE registries. The ACTION Registry–GWTG is a
ational database that currently has 291 participating sites in
he U.S., with data collection beginning January 1, 2007. The
RUSADE registry is a voluntary quality improvement ini-
iative that began data collection on unstable angina and
STEMI patients in November 2001 (with retrospective data
ollection from January 2001) and ended December 31, 2006,
nd had 568 nationally participating sites (15).
atient inclusion criteria. Between January 1, 2002, and
ecember 31, 2006, 175,394 NSTEMI patients were in-
luded in the CRUSADE initiative. Between January 1,
bbreviations
nd Acronyms
ABG  coronary artery
ypass graft surgery
HF  congestive heart
ailure
K-MB  creatine kinase-
yocardial band
QR  interquartile range
I  myocardial infarction
STEMI  non–ST-segment
levation myocardial
nfarction
CI  percutaneous
oronary intervention
TEMI  ST-segment
levation myocardial
nfarction007, and June 30, 2008, 47,971 NSTEMI patients werencluded in the ACTION Registry–GWTG. The
STEMI patients in both the CRUSADE and ACTION
egistry–GWTG programs were designated by the follow-
ng criteria: ischemic symptoms within 24 h of presentation
ith elevation of creatine kinase-myocardial band (CK-
B) and/or troponin I/T levels above the local laboratory
pper limit of normal.
For the analysis of temporal changes in the rate and timing
f CABG, after exclusions, we yielded a sample size of 109,169
STEMI patients (Fig. 1). To analyze the impact of the
iming of CABG on in-hospital clinical outcomes in the
CTION Registry–GWTG, after exclusions, we yielded a
ample size of 21,470 patients (Fig. 2). We used only the
CTION Registry–GWTG database to explore timing of
ABG on in-hospital outcomes, because of difficulties in
erging the CRUSADE and ACTION databases due to
iffering data elements in the earlier version of the CRUSADE
ase report form.
ata collection and study deﬁnitions. No consensus time
pecification exists to define early versus late CABG after
STEMI. Because several prior studies defined early
ABG as occurring 48 h and late CABG as 48 h after
ospital admission (5–7,12), we prospectively used this
efinition, categorizing the time to CABG as the time from
ospital arrival to first skin incision.
Data were abstracted by a trained data collector at each
ospital. Reported descriptive data include demographic
nd historical information (including age, sex, race, history
f hypertension, diabetes, peripheral arterial disease, dyslip-
demia, prior myocardial infarction [MI], prior revascular-
Exclusion Criteria:
Patients in hospital without surgical capabilities (N=43,538)
Patients contraindicated to catheterization (N=20,219)
Transferred out patients (N=4,098)
Patients with missing CABG and/or timing info (N=2207)
109,169 NSTEMI
223,365 NSTEMI
Patients receiving PCI prior to CABG (N=652)
Transferred in patients (N=43,482)       
Figure 1. Patient Criteria for Rate and Timing of CABG in the CRUSADE
and ACTION Registries
ACTION  Acute Coronary Treatment and Intervention Outcomes Network;
CABG  coronary artery bypass graft surgery; CRUSADE  Can Rapid Risk
Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes with
Early Implementation of the American College of Cardiology/American
Heart Association Guidelines; NSTEMI  non–ST-segment elevation myocar-
dial infarction; PCI  percutaneous coronary intervention.
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421zation, prior stroke, current/recent smoker, insurance sta-
us, and home medications); physical findings and
aboratory data present at arrival to the hospital (including
eart rate, blood pressure, signs of congestive heart failure
CHF], initial hematocrit, and serum creatinine); and in-
ospital medications administered, including acute medica-
ions (within 24 h of hospital arrival) and medications used
ny time during hospital stay.
In-hospital outcomes were recorded by site data collec-
ors, including all cause mortality, myocardial (re)infarction,
ardiogenic shock, CHF, stroke, and bleeding defined as
nits of red blood cells transfused; however, these outcomes
ere not independently adjudicated. A composite outcome
f death, MI, cardiogenic shock, or CHF was defined as the
rimary efficacy outcome. Myocardial (re)infarction was
efined as clinical signs and symptoms of ischemia distinct
rom the presenting ischemic event, either occurring before
ABG or spontaneously 72 h after CABG. For sponta-
eous MI, patients were required to have either new
schemic Q waves on electrocardiogram or an elevated
K-MB or troponin above the upper limit of normal, at
east 25% above the most recent value if the most recent
ardiac markers before MI were normal or 50% above the
ost recent value if the cardiac markers were above the
pper limit of normal. For MI within the first 72 h after
ABG, either new pathologic Q waves on electrocardio-
ram or an increase in biomarkers 5 times the upper limit
Exclusion Criteria:
Patients in hospital without surgical capabilities (N=7,270)
Patients contraindicated to catheterization (N=6,152)
Transferred out patients (N=686)
Patients with missing CABG and/or timing info (N=252)
21,470 NSTEMI
2,647 CABG
47,971 NSTEMI
825 Early 1,822 Late
Patients receiving PCI prior to CABG (N=137)
Transferred in patients (N=12,004)       
Figure 2. Patient Criteria for Timing of CABG in ACTION Registry–GWTG
GTWG  Get With The Guidelines; other abbreviations as in Figure 1.f normal per the local laboratory was required. If patients iad cardiac biomarkers above the upper limit of normal
efore CABG, then the increase in CK-MB had to be
50% above the most recent value.
For the outcomes of cardiogenic shock and CHF, only
ew shock or CHF was included as an end point event such
hat individuals presenting with shock or heart failure could
ot meet the end point of new shock or heart failure.
istorically, postoperative bleeding in CABG patients has
een defined by the number of required transfused red blood
ell units. Thus, the prospective definition of bleeding used
or the present analyses was transfusion 2 red blood cell
nits. Secondary bleeding definitions included the propor-
ion receiving any red blood cell transfusion and the pro-
ortion receiving 4 red blood cell units.
The GRACE (Global Registry of Acute Coronary
vents) risk score, a validated prognostic indicator of
n-hospital events (16), was calculated for patients in the
CTION Registry–GWTG to better characterize the risk
rofile of patients in the early and late CABG groups.
ecause the ACTION Registry–GWTG collects signs
yes/no) and severity of heart failure (mild, severe, shock),
or the variable of Killip class, we defined Killip 1 as no
eart failure, Killip 2 as mild heart failure, Killip 3 as severe,
nd Killip 4 as cardiogenic shock. Because the variable of
ardiac arrest on admission was not collected, this was not
ncluded in the calculated GRACE scores.
tatistical analysis. Baseline patient characteristics, clinical
actors, hospital characteristics, in-hospital care patterns,
nd in-hospital outcomes were compared between early and
ate CABG groups. In addition, graphical displays of rates
f CABG and timing of CABG (e.g., rates of early CABG)
cross the study period were presented. Median values with
nterquartile ranges (IQRs) (IQR: 25th, 75th percentiles)
ere used to describe continuous variables, and percentages
ere reported for categorical variables. Continuous and
rdinal categorical variables were compared with stratum-
djusted Wilcoxon rank sum test, whereas nominal categor-
cal variables were compared with stratum-adjusted chi-
quare test for trend where stratification is by hospital.
To explore the relationship between early CABG (vs. late
ABG) and in-hospital clinical outcomes, the generalized
stimating equations method for estimating marginal effects
f timing of CABG (early vs. late) status was used. This
ethod produces estimates similar to those from ordinary
ogistic regression, but the estimated variances are adjusted
or the correlation of outcomes within a hospital. An
xchangeable correlation structure was used for this analysis
17,18). Furthermore, the analyses accounted for both
ithin-center correlation and among-center variation.
Patient-specific variables in the models included age,
ale sex, body mass index, white race, hypertension, dia-
etes, smoking status, hypercholesterolemia, prior periph-
ral artery disease, prior MI, prior percutaneous coronary
ntervention (PCI), prior CABG, prior CHF, prior stroke,
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422urrent dialysis, baseline serum creatinine, signs of CHF at
resentation, heart rate, and systolic blood pressure on
dmission. Additionally, home clopidogrel (daily prescribed
lopidogrel), acute clopidogrel (prescribed within first 24 h),
cute clopidogrel contraindications, and time of presenta-
ion on weekday or weekend (8:00 AM to 4:00 PM, 4:00 PM
o 12:00 AM, or 12:00 AM to 8:00 AM) were included.
To determine factors associated with delayed CABG, a
ultivariable logistic generalized estimating equations
odel was used adjusting for the aforementioned covariates
except for home clopidogrel, acute clopidogrel contraindi-
ations, and time of presentation), including other medica-
ions (aspirin, beta blocker, low molecular weight heparin,
nfractionated heparin, angiotensin-converting enzyme in-
ibitor, angiotensin receptor blocker, and statin) and pro-
ider and hospital characteristics (physician specialty, total
umber of hospital beds, region of the country, and type of
ospital [academic or nonacademic]). All the variables listed
re included in each outcome model; furthermore, the
ariables were determined through clinical input from the
nvestigators of this study.
A p value of0.05 was considered statistically significant
or all tests, and all tests of statistical significance were
-tailed. All analyses were performed with SAS software
version 9.2, SAS Institute, Cary, North Carolina).
esults
emporal trends in CABG use and timing from 2002 to 2008.
n-hospital CABG rates after NSTEMI did not change
ignificantly from 2002 to 2008 (ptrend  0.08), ranging
etween 11% and 13% (Fig. 3A). There was also no
ignificant difference in the mean proportion of patients
ndergoing early (30.4%) or late (69.7%) CABG across time
ptrend  0.28) (Fig. 3B).
Figure 3. Rate of In-Hospital CABG by Year of Presentation and by Timing
(A) Rate of in-hospital CABG by year of presentation in the CRUSADE and ACT
registries. *N  number of patients undergoing in-hospital CABG. Abbreviations as ingiography and CABG timing in ACTION Registry–GWTG.
f the 2,647 (12.3%) NSTEMI patients who underwent
n-hospital CABG in the ACTION Registry–GWTG
rom 2007 to 2008, 825 (31.2%) underwent early CABG
nd 1,822 (68.8%) underwent late CABG. Overall, the
edian time from arrival to CABG for NSTEMI patients
as 72.9 h (IQR: 42.0 to 121.8). The median time to
ABG was 28.9 h (IQR: 18.5 to 40.4) for early CABG
atients and 101.8 h (IQR: 70.8 to 147.1) for late CABG
atients. The median time from hospital arrival to cardiac
atheterization for early and late groups was 8.7 h (IQR: 3.0
o 17.6) and 27.6 h (IQR: 16.2 to 50.2), respectively. The
edian time between cardiac catheterization and CABG
or early and late groups was 18.6 (IQR: 5.1 to 23.3) and
9.0 h (IQR: 44.3 to 110.2), respectively (Fig. 4).
linical characteristics associated with CABG timing. Base-
ine characteristics and presenting physical findings strati-
CRUSADE and ACTION Registries
gistries. (B) Rate of in-hospital CABG by timing in the CRUSADE and ACTION
Hours
8.7
27.6
18.6
69.0
Figure 4. Median Time From Arrival to CABG by Timing of CABG
cath  catheterization; other abbreviations as in Figure 1.in the
ION re
n Figure 1.
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423ed by CABG timing are shown in Table 1. Compared
ith NSTEMI patients undergoing early CABG, patients
ndergoing late CABG had a higher-risk clinical profile
nd a slightly higher median GRACE risk score (127 vs.
21, p  0.03). Compared with patients undergoing early
ABG, those undergoing late CABG after NSTEMI were
ore likely to have signs of CHF on arrival. The NSTEMI
atients treated with earlier CABG were more likely to have
Table 1. Clinical Characteristics of Patients Undergo
Age (yrs)* 63
Sex (%)
Male
Female
Race (%)
Caucasian
Black
Hispanic
Asian
Hypertension (%)
Diabetes (%)
Dyslipidemia (%)
Peripheral artery disease (%)
Prior myocardial infarction (%)
Prior percutaneous coronary intervention (%)
Prior coronary artery bypass grafting (%)
Prior congestive heart failure (%)
Prior stroke (%)
Baseline creatinine (mg/dl)* 1
Baseline hematocrit (%) * 42
Admission systolic blood pressure (mm Hg)* 147
Admission heart rate (beats/min) 84
Signs of heart failure (%)
Type of heart failure (%)
Mild
Severe
Cardiogenic shock
Left ventricular ejection fraction (%)
50%
40%–50%
25%–40%
25%
Hospital type (%)
Academic
Nonacademic
Insurance status (%)
Health maintenance organization/private
Medicare
Medicaid
Military/Veterans Affairs Medical Center
Self/none
*Presented as median values (25th, 75th percentiles).CABG coronary artery bypass graft surgery.ardiogenic shock on presentation, although not statistically
ignificant in the comparison of types of CHF.
n-hospital medications. In-hospital medications adminis-
ered within 24 h of hospital arrival are shown in Table 2.
ompared with patients undergoing early CABG, those
ndergoing late CABG were more likely to have received
lopidogrel, statins, low molecular weight heparin, and
ngiotensin-converting enzyme inhibitors. However, early
rly Versus Late CABG
rly
825)
Late
(n  1,822) p Value
0, 72.0) 65.0 (57.0, 75.0) 0.02
0.002
.5 68.3
.5 31.7
0.33
.3 83.6
.1 8.3
.4 2.0
.0 4.2
.7 76.6 0.0001
.2 39.5 0.0001
.2 58.1 0.47
.8 12.7 0.001
.7 21.6 0.01
.8 17.9 0.08
.2 4.9 0.03
.0 10.1 0.0001
.7 8.8 0.04
, 1.2) 1.1 (0.9, 1.3) 0.005
9, 45.4) 41.2 (37.4, 44.5) 0.0001
.0, 166.5) 150.0 (130.0, 170.0) 0.27
5, 97.0) 86.0 (73.0, 101.5) 0.02
.1 21.8 0.0001
0.14
.0 66.1
.0 29.9
.0 1.8
0.44
.4 53.1
.4 22.2
.3 19.9
.9 4.5
0.08
.5 26.7
.5 73.3
0.96
.5 54.7
.8 30.8
.4 4.3
.7 1.2
.1 8.3ing Ea
Ea
(n 
.0 (55.
75
24
86
5
3
4
66
31
56
7
16
15
3
4
5
.0 (0.9
.5 (38.
.0 (129
.0 (71.
12
53
26
15
52
24
19
3
23
76
60
25
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424ABG patients were more likely to receive glycoprotein
Ib/IIIa inhibitors and unfractionated heparin than late
ABG patients.
everity of coronary disease and infarct size. Both the early
nd late CABG groups had primarily 3-vessel disease on
oronary angiography (73.7% vs. 72.8%, p  0.40). Al-
hough there were no differences in the median peak
roponin levels between the early and late CABG groups
27.5 upper limit of normal vs. 23.2 upper limit of
ormal, p  0.19), the median peak CK-MB was modestly
igher in the early CABG group (5.1 upper limit of
ormal vs. 4.7 upper limit of normal, p  0.01).
ultivariable analyses to identify factors associated with
ABG timing. Factors associated with delayed CABG after
ultivariable adjustment are shown in Table 3 and include
Table 2. Medications Within 24 Hours by Timing of CABG
Early
(n  825)
Late
(n  1,822) p Value
Aspirin (%) 98.4 97.8 0.18
Beta-blocker (%) 93.1 94.4 0.59
Angiotensin-converting enzyme inhibitor (%) 34.3 46.2 0.0001
Statin (%) 46.7 59.5 0.0001
Clopidogrel (%) 27.3 36.9 0.01
Glycoprotein IIb/IIIa inhibitor (%) 38.3 37.9 0.04
Anticoagulants (%)*
Unfractionated heparin 72.5 61.5 0.0001
Low molecular weight heparin 29.9 43.7 0.0001
Bivalirudin 0.8 0.8 0.39
*Recorded as anytime during hospital stay rather than within 24 h.
Abbreviations as in Table 1.
Table 3. Multivariable Model of Factors Associated With Delayed CABG
Odds
Ratio
95% Confidence
Interval p Value
Demographic data
Age (per 5-yr increase) 1.08 1.04–1.13 0.0003
Clinical characteristics
Current/recent smoker 1.44 1.13–1.82 0.003
Signs of congestive heart failure 1.54 1.15–2.06 0.004
Hypertension 1.27 1.06–1.52 0.009
Baseline hematocrit (per 1% decrease) 1.02 1.01–1.04 0.009
Prior congestive heart failure 1.67 1.12–2.49 0.01
Dyslipidemia 0.79 0.63–0.97 0.03
Inpatient medications
Acute statin 1.60 1.34–1.90 0.0001
Acute clopidogrel 1.83 1.42–2.36 0.0001
Acute angiotensin-converting enzyme
inhibitor
1.46 1.19–1.79 0.0003
Acute angiotensin receptor blocker 1.67 1.21–2.32 0.002
Any unfractionated heparin 0.75 0.59–0.95 0.02
Any low molecular weight heparin 1.68 1.33–2.13 0.0001CAbbreviations as in Table 1.n-hospital administration of clopidogrel and low molecular
eight heparin as well as older age, hypertension, smoking,
vidence of CHF, and lower hematocrit.
utcomes. There were no differences in unadjusted in-
ospital adverse outcomes between those undergoing early
ersus late CABG, including death (3.6% vs. 3.8%, p 
.56), MI (1.2% vs. 1.7%, p  0.13), CHF (7.8% vs. 8.0%,
 0.45), shock (5.9% vs. 4.0%, p  0.06), or stroke (2.2%
s. 1.7%, p  0.63). The primary composite outcome
ccurred in 12.6% of the early subgroup versus 12.4% of the
ate subgroup (p  0.42). After multivariable adjustment,
n-hospital outcomes remained similar for the early and
elayed CABG subgroups (Fig. 5). Patients undergoing late
urgery were more likely to receive a red blood cell transfu-
ion (65.5% vs. 56.7%, p  0.0001) including 2 U of
acked red blood cells (54.9% vs. 48.1%, p  0.006), but
here were no differences in those receiving4 U (28.0% vs.
3.8%, p  0.41). Median length of hospital stay was
ignificantly longer in the late CABG group (11 vs. 7 days,
 0.0001) than in the early CABG group.
iscussion
ecent trends in the management of NSTEMI include
ncreasing application of an early invasive treatment strat-
gy. Among individuals with extensive coronary artery
isease for whom CABG was previously the preferred
reatment option, PCI—particularly with drug-eluting
tents—has become a commonly employed revasculariza-
ion alternative (19). Surprisingly, in the present study we
ound that in-hospital CABG rates after NSTEMI did not
hange between 2002 and 2008. This finding was unex-
ected, because prior studies have revealed an increase in
CI use over time with a reduction in the rates of CABG
18–20). However, our study extends findings by Gogo
t al. (20), who analyzed patients from 2002 to 2005 in the
Early CABG better Late CABG better
0.
1 1 10
Composite Outcomes
Stroke
CHF
Death or Myocardial Infarction
Myocardial Infarction
Death
Figure 5. Adjusted Odds Ratios and 95% Confidence Interval for
In-Hospital Outcomes for Early CABG (vs. Late CABG)
*Composite outcomes  death, myocardial infarction, congestive heart fail-
ure, or cardiogenic shock. CABG  coronary artery bypass graft surgery;
CHF  congestive heart failure.RUSADE registry and found no change in CABG rates
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425mong patients with severe coronary disease receiving in-
ospital CABG. We also found no change in the timing of
ABG, with a consistent 30% of individuals undergoing
arly (48 h) CABG from 2002 to 2008.
Several potential factors might contribute to the failure of
he expected decline in CABG rates. First, as use of cardiac
atheterization for NSTEMI has increased over time
21,22), so has the diagnosis of extensive coronary artery
isease. Thus, the proportion of patients undergoing surgi-
al revascularization after an NSTEMI might have re-
ained stable as the pool of patients identified with severe
oronary artery disease has increased. Second, the debate
ver whether patients with multivessel disease fare better
ith PCI versus CABG is ongoing and remains particularly
ontentious in the subset of diabetic patients (23–29).
lmost three-quarters of the patients in this study had
-vessel coronary artery disease on coronary angiography,
nd over 30% of patients were diabetic. Recommendations
avoring CABG over PCI in this subgroup of patients likely
ontributed to persistent high use of CABG.
actors inﬂuencing the timing of CABG after NSTEMI. Late
ABG was associated with a higher risk profile, along with
ncreased statin, clopidogrel, angiotensin-converting enzyme
nhibitor, and low molecular weight heparin administration
uring the hospital stay. Although the influence of statins and
ngiotensin-converting enzyme inhibitors is likely a reflection
f existing cardiovascular disease, administration of clopidogrel
nd low molecular weight heparin might have directly affected
ABG timing. Several studies have confirmed higher bleeding
ates in patients receiving clopidogrel within 5 to 7 days before
ABG (30–33). Additionally, prior studies have revealed
igher bleeding rates in patients receiving low molecular
eight heparin immediately before CABG (34–36), and the
merican College of Cardiology/American Heart Association
nstable Angina/NSTEMI practice guidelines recommend
iscontinuation of enoxaparin 12 to 24 h before CABG (14).
hus, decisions regarding CABG timing might be driven by
hysicians upstream of the cardiac surgeon, because early
dministration of clopidogrel and low molecular weight hep-
rin by nonsurgeon physicians might contribute to delayed
ABG.
Patients undergoing early CABG underwent catheteriza-
ion a median of 18.9 h sooner after hospital arrival than
atients undergoing late CABG. Thus, a key variable
nfluencing CABG delay is delay to cardiac catheterization,
finding that further supports that decisions regarding
ABG timing might be influenced by physicians upstream
f the cardiac surgeon.
ssociation between CABG timing and outcomes. Unad-
usted and adjusted analyses revealed no differences in out-
omes between patients undergoing early or late CABG, and
atients undergoing early CABG were less likely to receive red
lood cell transfusions. Most studies examining the timing of
urgery after an MI have not discriminated between STEMI cnd NSTEMI and have grouped patients under the umbrella
f “acute myocardial infarction” (2–5,7,11,12,37–48). How-
ver, the distinction between STEMI and NTSTEMI is
ritical, because the treatments before CABG and early out-
omes differ markedly between the 2 types of MIs. The few
tudies specifically examining the timing of surgical revascu-
arization after an NSTEMI are conflicting. Deeik et al. (9)
eported that waiting 3 to 5 days for CABG after a nontrans-
ural MI resulted in similar postoperative outcomes of rein-
arction and death as compared with a control group of patients
ndergoing CABG for stable coronary artery disease. How-
ver, Braxton et al. (6) found no difference in surgical mortality
ates, comparing patients with non–Q-wave MI undergoing
ABG within 48 h with those undergoing elective CABG.
ur study is unique in that not only does it detail the outcomes
pecifically of NSTEMI patients but the patients in our study
ave been treated in the contemporary era of aggressive
harmacological and interventional therapy for NSTEMI.
tudy limitations. This study has the inherent limitations of
bservational registries, because the timing of referral for
oth cardiac catheterization and CABG was left to the
iscretion of the treating physician. Furthermore, there
ight have been a survivor bias favoring the late CABG
roup, because patients who died early could not undergo
ate CABG. This limitation, however, only strengthens our
nding of no apparent benefit associated with routine
ABG delay. By contrast, the possibility of a selection bias
avoring the early CABG group also exists, because patients
ndergoing late CABG had more high-risk clinical features.
lthough we attempted to account for these factors through
omprehensive multivariable analyses, it is possible that
ther unmeasured factors could also have contributed to
ABG timing and also influenced outcomes. Additionally,
here was a lack of adjudication for outcomes. Moreover,
nly the time of first red blood cell transfusion was collected,
o it is not possible to determine whether subsequent red
lood cell transfusions were administered pre-operatively or
ost-operatively. This study only performed follow-up
hrough hospital discharge, and additional study is needed
o correlate findings with longer-term outcomes up to 12
onths and beyond. The median GRACE risk score of the
ohort was 125, well within the intermediate-risk range.
dditional study is needed to determine whether delay in
ABG is beneficial in higher-risk individuals. Potentially
he outcome models could be overfitted and thus would fail
o replicate in future samples.
onclusions
he rates of in-hospital CABG and timing of CABG after
STEMI have not changed over the past 6 years. In the
urrent era, CABG is delayed more often in higher-risk
atients, and the delay seems to happen “upstream” of the
ardiac surgeon. Process factors associated with delayed
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426ABG include delay to cardiac catheterization and treat-
ent with clopidogrel and low molecular weight heparin.
mportantly, unadjusted and adjusted outcomes seem sim-
lar between those undergoing early CABG and those
ndergoing delayed CABG. Moreover, with early CABG,
leeding rates are lower and hospital stay is shorter than
ith late CABG. In conclusion, most NSTEMI patients
ndergo late CABG more than 48 h after hospital arrival,
nd although these patients have higher-risk clinical char-
cteristics, they have the same risk of adverse clinical
utcomes compared with patients who undergo early
ABG in this study. These results suggest that delaying
urgery routinely in all patients after uncomplicated
STEMI might increase resource use without improving
utcomes. Additionally, the timing of CABG for NSTEMI
atients might be appropriately determined by clinicians to
inimize the risk of adverse clinical events.
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